Updated Nov. 17, 2026, 9:37 p.m. ET
The White House has pulled Dr. Heidi Overton‘s nomination to lead the Food and Drug Administration, a White House official confirmed to USA TODAY on Nov. 17, a day before a Senate committee was scheduled to vote on whether to advance her nomination.
The decision ends Overton’s bid to lead the FDA after questions emerged about whether she had enough support to win Senate confirmation. A vote by the Senate Health, Education, Labor and Pensions Committee had been scheduled for Nov. 18. The move was first reported by Axios on Nov. 17.
With Democrats expected to oppose her nomination, Overton needed unanimous Republican support on the 21-member Senate Health, Education, Labor and Pensions Committee to advance to the full Senate.
The withdrawal leaves the Trump administration searching for a new leader for the FDA, a key health agency overseeing the regulation of prescription drugs, vaccines, medical devices and food safety. The search comes as Health and Human Services Secretary Robert F. Kennedy Jr. continues to pursue his “Make America Healthy Again” agenda.
The FDA has faced significant upheaval during Trump’s second term, including declining morale following workforce cuts across the Health and Human Services Department ordered by Kennedy. The agency has lost more than 3,000 employees over the past year, including senior leaders, and faces pressure to restore confidence among industry and public health groups.
Trump selected White House aide to lead the FDA
President Donald Trump nominated Overton in August, tapping a White House policy aide to lead an agency that has faced controversies over vaccines, drug approvals and abortion-related policy.
Overton serves as deputy director of the White House Domestic Policy Council and previously worked at the America First Policy Institute, a conservative think tank. She earned her medical degree from the University of New Mexico, trained in general surgery at Johns Hopkins and pursued clinical-investigation research training at the Johns Hopkins Bloomberg School of Public Health.
When announcing the nomination, Trump said Overton would advance his “America First” policies.
“She is known to take on the HARDEST issues, and bring me solutions that work best for the Country,” Trump wrote in a Truth Social post at the time. “We need her leadership at the FDA now to ensure that the U.S. remains the WORLD LEADER for Scientific Discovery and CURES.”
Her nomination followed the departure of former FDA Commissioner Marty Makary in May and came as administration health officials pursued several controversial initiatives, including efforts related to vaccines, autism research and the abortion pill.
Overton faced sharp questioning from senators during a confirmation hearing in September over vaccine policy and whether she would keep politics out of FDA decision-making.
Republican Louisiana Sen. Bill Cassidy, a doctor, pressed her to affirm the safety of the measles, mumps, and rubella (MMR) vaccine and criticized her support for a Trump-backed plan to split the childhood vaccination schedule into additional doses.
Democrats also scrutinized her anti-abortion views and questioned her past statements on abortion rights. Overton had called the Supreme Court’s 2022 decision overturning Roe v. Wade “a huge victory for life.”
Contributing: Reuters
This story was updated with new information.











Leave a Reply